Association between MTHFR A1298C polymorphism and hepatocellular carcinoma risk

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• Hepatocarcinogenesis is a multifaceted process influenced by numerous factors.
• Previous studies on the MTHFR A1298C polymorphism and hepatocellular carcinoma (HCC) risk have yielded inconsistent findings.
• A comprehensive meta-analysis is needed to clarify the association between MTHFR A1298C polymorphism and HCC risk.

Purpose of the Study:

• To conduct a meta-analysis to resolve conflicting results regarding MTHFR A1298C polymorphism and HCC risk.
• To evaluate the overall correlation between MTHFR A1298C polymorphism and hepatocellular carcinoma risk using a large sample size.

Main Methods:

• A systematic literature search was performed across PubMed, EMBASE, and CNKI databases.
• Seven studies, comprising 2035 cases and 3096 controls, were included in the meta-analysis.
• Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed or random effects models to assess heterogeneity and publication bias.

Main Results:

• The MTHFR A1298C polymorphism showed no significant association with HCC risk (OR=1.01, 95% CI=0.90-1.13).
• Subgroup analyses by ethnicity (Asian population) and control source (population-based and hospital-based) also revealed no significant correlation with HCC risk.
• Specific results for Asian populations (OR=1.02, 95% CI=0.91-1.14), population-based controls (OR=0.97, 95% CI=0.83-1.15), and hospital-based controls (OR=1.04, 95% CI=0.89-1.21) further support the lack of association.

Conclusions:

• This meta-analysis suggests that the MTHFR A1298C polymorphism is unlikely to be a significant risk factor for hepatocellular carcinoma.
• The findings contribute to a clearer understanding of the genetic factors influencing hepatocarcinogenesis.